According to a recent market study published by Growth Market Reports, titled, “Global Acute on Chronic Liver Failure Treatment Market is segmented into by type, by indication, by treatment, by application, and by Region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 6,025.8 Million in 2022 and is expected to grow at a growth rate of 6.5% by the year 2031.

Acute-on-chronic liver failure (ACLF) is a distinct clinical syndrome characterized by liver failure, due to an acute hepatic injury on an underlying chronic liver disease with high 28-day mortality. ACLF presents a challenge for both hepatologists and intensivists to treat, due to its rapid rate of progression. There are variations in its definition at present, leading to descriptions of various clinical phenotypes. Patients with chronic hepatitis B (CHB) and Hepatitis B virus (HBV)-related cirrhosis are also prone to develop hepatic or extrahepatic failures when they develop a superadded insult. Acute hepatic insults are caused by alcohol, hepatotropic viruses, and drugs; whereas chronic liver disease is generally caused by cirrhosis, hepatitis B or C, and non-alcoholic steatohepatitis (NASH).

Get Sample Report @ https://growthmarketreports.com/request-sample/5866

Based on type, the global acute on chronic liver failure treatment market is segregated into Type-A ACLF, Type-B ACLF, and Type-C ACLF. The Type-C ACLF segment is expected to hold a significant share of the market during the forecast period, due to increasing diagnosis of the liver disease and ACLF at this stage. Type-A ACLF is an acute worsening of liver function in a patient with chronic liver disease. Type-B ACLF happens when acute decompensation occurs in patients with cirrhosis. Type-C ACLF is acute worsening of liver function in decompensated cirrhotic. Type-C ACLF is diagnosed when there are three or more organ failures of any combination. The Type-B ACLF segment is projected to expand at a significant CAGR during the forecast period, owing to rising number of cirrhosis cases globally.

In terms of indication, the global acute on chronic liver failure treatment market is bifurcated into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), and others. The hepatitis segment is expected to hold a significant share of the market, as around 350 million people globally are chronically infected with hepatitis B virus; 75% of these cases are in Asia Pacific alone, where CHB is a leading cause of liver disease-related mortality. Research studies suggest that between 15% and 37% of patients with HBV infection have spontaneous acute exacerbations within 4 years. Some of these patients develop liver failure during such exacerbations and are labelled as acute-on-chronic liver failure. The mortality rate for these patients is reported to be as high as between 30% and 70%. The non-alcoholic fatty liver disease (NAFLD) segment is projected to expand at a significant CAGR during the forecast period, due rapidly increasing prevalence of NAFLD in North America and Europe.

Based on treatment the global acute on chronic liver failure treatment market is segmented into surgery and medication. The surgery segment is expected to hold a significant share of the market, as the high and increasing cirrhosis burden heightens the need for liver transplantation (LT). In 2021, 34,694 liver transplants were performed globally, an increase of 6.5% from 2020 and a 20% increase from 2015 (living or deceased). The use of living donors, donation after circulatory death (DCD) donors, and extended criteria donors represent important means of expanding the donor pool. Data from the study from liver-chronic liver failure (EASL-CLIF) Consortium and called the EASL-CLIF Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC) shows that 9% of patients satisfying the ACLF criteria can be transplanted within 28 days and 15% within 90 days after admission. In patients with ACLF grade 2 or 3, survival without LT was<20%, which increased to 80% at 1 year in those who received LT. However, less than one fourth of the patients are fortunate enough to go through LT.

In terms of application, the global acute on chronic liver failure treatment market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment is expected to hold XX% share of the market in 2022, as surgical expertise and specialized surgeons are available in hospitals. Several innovations and technologies associated with hospitals are expected to improve the pain management of patients suffering from end-stage liver diseases in the hospital. The liver transplantation and related treatment is expected to grow in hospitals, due to suitable clinical outcomes and successful surgeries that are performed by specialists. This factor contributes to the growth of the market.

The outbreak of coronavirus disease in 2019 (COVID-19) had an impact on the global acute on chronic liver failure treatment market. COVID-19 led to disruptions in healthcare systems globally, as resources were diverted to manage the surge in the number of COVID-19 cases. Elective procedures, including liver transplants, were postponed or cancelled in many healthcare facilities to prioritize urgent and essential care. This resulted in a decline in the number of liver transplant procedures performed, leading to a decrease in demand for liver donors. During the pandemic, many individuals delayed while seeking medical care, due to concerns about potential exposure to the virus or restrictions on non-essential medical visits. Routine screening and diagnostic procedures, including those related to biliary diseases, were postponed or avoided by patients. This led to a decrease in patient visits and screenings, which negatively impacted the demand for ACLF treatment.

As per growth market reports by industry analyst Divyanka Sankhe, “Rise in Number of Hepatologists globally, Increase in Awareness about the Liver Diseases and Epidemiology of Liver Cirrhosis and Associated Complications is expected to propel the number of Acute on Chronic Liver Failure Treatment used, which in turn is anticipated to drive the market during the forecast period.”

Supply chain management is an essential part of any business. The supply chain in the acute on chronic liver failure treatment industry is a complex process due to regulations, safety, and high costs. The supply chain is the process, through which controlled substances are manufactured, marketed, promoted, distributed, and dispensed. It includes strategic management of activities in the conversion of materials and information to finished products.

Key Takeaways from the Study:

The players in the global acute on chronic liver failure treatment market include Sun Pharmaceutical Industries Ltd., Aurobindo Pharma., Pfizer Inc., GSK plc., Dr. Reddy’s Laboratories Ltd., Cipla Inc., Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company

Report Metric

Details

Market Value in 2022

US$ 6,025.8 Million

Market Growth Rate (from 2020 to 2028)

6.5%

Historical Data

2016 & 2031

Base Year

2022

Forecast Period

2023 – 2031

Units Considered

Value (US$ Million)

Market Segments

By Type, By Indication, By Treatment, By Application, and By Region

Key Companies Profiled

Sun Pharmaceutical Industries Ltd., Aurobindo Pharma., Pfizer Inc., GSK plc., Dr. Reddy’s Laboratories Ltd., Cipla Inc., Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience:

  • Supply-side: Manufacturer and distributors.

  • Demand Side: Hospitals, Ambulatory Surgical Centers, Clinics.

  • Regulatory Side: Approved regulatory bodies.